Contents - Pharma Technology Focus | Issue 102 | January 2021

12/18/2020 00:00:00

Go to article: Home | Is Joe Biden good news for US pharma?Go to article: In this issue Go to article: Contents Go to article: Mimotopes Go to article: Briefing Go to article: Industry news Go to article: The pharma industry briefing Go to article: Covid-19 executive briefing by GlobalData Go to article: HOF Sonderanlagenbau Company Insight Go to article: HOF Sonderanlagenbau Go to article: Comment Go to article: Pipeline agents in the RA market Go to article: US seeing alarming increases in Covid-19 cases Go to article: IDMP: Where are we now and what lies ahead?Go to article: The rising role of the microbiome Go to article: What the pandemic highlights about IDMP’s potential Go to article: In Depth Go to article: Solving the puzzle of Hepatitis C Go to article: Why is President-elect Joe Biden a good pick for the pharma industry?Go to article: Is self-medication the future of pharma?Go to article: Restricted growth: Challenging attitudes to achondroplasia Go to article: How do you fast-track a vaccine? UCL scientists weigh in Go to article: Fraudulent pharmaceuticals: the legacy of anti-counterfeit packaging Go to article: Are healthcare’s sustainability goals bold enough?Go to article: New Zealand: a promising destination for trials in a post-Covid-19 world?Go to article: In Data Go to article: Inside the deal Go to article: Deals analysis Go to article: The pharma industry key list Go to article: Global markets and indices Go to article: Macro-economic indicators Go to article: Macro-economic indicators (page 2)Go to article: Events Go to article: Next issue